Risk acceptance in multiple sclerosis patients on natalizumab treatment

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Tur, Carmen ^a   Tintoré, Mar ^a   Vidal Jordana, Ángela ^a   Bichuetti, Denis ^a,b   González, Pablo Nieto ^a,c   Arévalo, María Jesús ^a   Arrambide, Georgina ^a   Anglada, Elisenda ^a   Galán, Ingrid ^a   Castilló, Joaquín ^a   Nos, Carlos ^a   Río, Jordi ^a   Martín, María Isabel ^a   Comabella, Manuel ^a   Sastre Garriga, Jaume ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; FEMALE; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROSIS; PATIENT ATTITUDE; PERSONALITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RISK ACCEPTANCE; RISK ACCEPTANCE SCORE; SCORING SYSTEM;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PERCEPTION; RISK FACTORS;

EID: 84892388359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082796     Document Type: Article

References (30)

1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648): 1502-1517. doi:10.1016/S0140-6736(08)61620-7. PubMed: 18970977.
2. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53(3): 466-472. doi:10.1212/WNL.53.3.466. PubMed: 10449105.
3. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1): 15-23. doi:10.1056/NEJMoa020696. PubMed: 12510038.
4. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9): 899-910. doi:10.1056/NEJMoa044397. PubMed: 16510744.
5. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9): 911-923. doi:10.1056/NEJMoa044396. PubMed: 16510745.
6. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5): 402-415. doi:10.1056/NEJMoa0907839. PubMed: 20089954.
7. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5): 387-401. doi:10.1056/NEJMoa0909494. PubMed: 20089952.
8. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L et al. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14): 1293-1303. doi:10.1056/NEJMoa1014656. PubMed: 21991951.
9. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66(6): 894-900. doi:10.1212/01.wnl.0000203121.04509.31. PubMed: 16567708.
10. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17): 1786-1801. doi:10.1056/NEJMoa0802670. PubMed: 18946064.
11. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856): 1819-1828. doi:10.1016/S0140-6736(12)61769-3. PubMed: 23122652.
12. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C et al. (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856): 1829-1839. doi:10.1016/S0140-6736(12)61768-1. PubMed: 23122650.
13. Administration USFaD. http://www.fda.gov. 10903 New Hampshire Avenue. Silver Spring, MD 20993. Ph. 1-888-INFO-FDA (1-888-463-6332) 2013 [February 2013]
14. Horga A, Castillo J, Rio J, Tintore M, Auger C et al. (2011) An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol 52(6): 321-330. PubMed: 21387248.
15. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R et al. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18(2): 143-152. doi:10.1177/1352458511435105. PubMed: 22312009.
16. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A et al. (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10(8): 745-758. doi:10.1016/S1474-4422(11)70149-1. PubMed: 21777829.
17. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20): 1870-1880. doi:10.1056/NEJMoa1107829. PubMed: 22591293.
18. Sandrock A, Hotermans C, Richman S (2011) Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCF antibody status. Neurology 76 (suppl 4): A248.
19. Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I et al. (2012) Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Mult Scler 18(8): 1193-1196. doi:10.1177/1352458512439238. PubMed: 22383232.
20. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3): 227-231. doi:10.1002/ana.410130302. PubMed: 6847134.
21. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1): 121-127. doi:10.1002/ana.1032. PubMed: 11456302.
22. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58(6): 840-846. doi:10.1002/ana.20703. PubMed: 16283615.
23. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11): 1444-1452. doi:10.1212/WNL.33.11.1444. PubMed: 6685237.
24. Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J et al. (2010) Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler 16(12): 1507-1512. doi:10.1177/1352458510379819. PubMed: 20826527.
25. a Dolores Avia Aranda (Author); R+D Department of TEA Editors (Translator) (2008) NEO PI-R, Inventario de Personalidad NEO-Revisado y NEO FFI, Inventario NEO reducido de cinco factores. R+D Department of TEA Editors
26. Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J et al. (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15(7): 848-853. doi:10.1177/1352458509104591. PubMed: 19542263.
27. Bruce JM, Lynch SG (2011) Personality traits in multiple sclerosis: association with mood and anxiety disorders. J Psychosom Res 70(5): 479-485. doi:10.1016/j.jpsychores.2010.12.010. PubMed: 21511079.
28. Taillefer SS, Kirmayer LJ, Robbins JM, Lasry JC (2003) Correlates of illness worry in chronic fatigue syndrome. J Psychosom Res 54(4): 331-337. doi:10.1016/S0022-3999(02)00332-X. PubMed: 12670610.
29. Bodini B, Cercignani M, Khaleeli Z, Miller DH, Ron M et al. (2013) Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years. Hum Brain Mapp 34(5): 1163-1172. doi:10.1002/hbm.21499. PubMed: 22328451.
30. Gourley SL, Olevska A, Zimmermann KS, Ressler KJ, Dileone RJ et al. (2013) The orbitofrontal cortex regulates outcome-based decision-making via the lateral striatum. Eur J Neurosci 38(3): 2382-2388. doi:10.1111/ejn.12239. PubMed: 23651226.